PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
NGeneBio has posted sharp revenue growth on the NGenePharma consolidation and NGS diagnostics expansion, but continues to post operating losses and negative cash flow while pursuing a capital reduction and rights offering to repair its balance sheet.
2025 consolidated revenue reached KRW 21.2bn, up sharply from KRW 5.7bn a year earlier, but the operating loss remained at KRW 8.3bn.
Quarterly revenue expanded steadily to KRW 12.0bn in Q1 2026 and KRW 12.5bn in Q2 2026.
The company acquired and merged pharmaceutical distributor NGenePharma in September 2025, broadening its revenue base.
In 2026 the company pursued a roughly KRW 22.4bn rights offering alongside a 3-for-1 capital reduction to address its balance sheet.
The company is pursuing overseas expansion and an AI precision-medicine business through EU CE-IVDR certification and an AI licensing deal with LG AI Research.
NGeneBio, founded in 2015 and listed on KOSDAQ in 2020, is a precision diagnostics platform company built on next-generation sequencing (NGS) technology.
It supplies gene-extraction panels and data-analysis software specialized for breast cancer, ovarian cancer and blood cancer, delivering products to more than 25 major domestic hospitals while expanding overseas exports.
In September 2025 the company acquired pharmaceutical distributor NGenePharma and immediately pursued a merger, broadening its portfolio beyond diagnostics into distribution. However, market commentary has noted that NGenePharma itself was not profitable at the time of acquisition.
The diagnostics segment has shown even growth at home and abroad, driven by expanded sales of blood-cancer and solid-tumor precision diagnostic products and rising test demand centered on major hospitals.
Overseas, the company became the first in Korea to obtain EU CE-IVDR certification for its breast and ovarian cancer diagnostic panel, aiming to expand its hereditary cancer and solid-tumor panels globally, while in Southeast Asia it has expanded from an initial Singapore foothold into Vietnam and Thailand.
In AI precision medicine, the company is pursuing commercialization of its NPAS pathology-analysis software built on LG AI Research's EXAONE Path 2.0, seeking new revenue streams through drug-development research collaborations with pharmaceutical companies and integrated AI-NGS companion diagnostics.
On the competitive front, the domestic precision diagnostics and MRD diagnostics space has seen a range of new entrants competing alongside NGeneBio.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.8B | -₩1.9B | −103.5% |
| 2025Q3 | ₩5.4B | -₩1.6B | −30.3% |
| 2025Q4 | ₩12B | -₩1.9B | −15.9% |
| 2026Q1 | ₩12B | -₩1.6B | −13.1% |
| 2026Q2 | ₩12.5B | -₩1.2B | −9.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩11B | -₩8.6B | -₩9.8B | −78.1% | −38.7% | 121.8% |
| 2023 | ₩4.4B | -₩13.4B | -₩12.8B | −308.6% | −78.4% | 160.5% |
| 2024 | ₩5.7B | -₩16.1B | -₩12.6B | −282.5% | −74.4% | 86.1% |
| 2025 | ₩21.2B | -₩8.3B | -₩5.5B | −39.0% | −24.1% | 220.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue fell from KRW 11.0bn in 2022 to KRW 4.4bn in 2023 and KRW 5.7bn in 2024, before rebounding more than threefold to KRW 21.2bn in 2025, largely on the consolidation effect of NGenePharma.
The operating loss widened from KRW 8.6bn in 2022 to KRW 13.4bn in 2023 and KRW 16.1bn in 2024, before narrowing to KRW 8.3bn in 2025, with the operating margin improving markedly from -308.6% in 2023 and -282.5% in 2024 to -39.0% in 2025.
Net loss attributable to owners also continued in the KRW 9.0-12.8bn range each year from 2022-2024 before narrowing to KRW 5.5bn in 2025. On a quarterly basis, revenue expanded clearly from KRW 5.4bn in Q3 2025 to KRW 12.0bn in Q4 2025, KRW 12.0bn in Q1 2026 and KRW 12.5bn in Q2 2026.
The quarterly operating loss also improved gradually, from KRW 1.87bn in Q2 2025 to KRW 1.19bn in Q2 2026. However, net income attributable to owners swung noticeably, turning positive at KRW 4.48bn in Q4 2025 before reverting to losses of KRW 4.19bn in Q1 2026 and KRW 3.43bn in Q2 2026.
Operating cash flow remained negative throughout 2022-2025 (KRW -7.8bn, -9.2bn, -12.4bn, -8.5bn), indicating that internal cash generation has not yet been secured despite top-line growth.
The debt ratio rose sharply from 86.1% in 2024 to 220.2% in 2025, showing that financial leverage climbed alongside the revenue expansion.
The NGS-based precision diagnostics market is a growing upstream industry driven by expanding demand for precision medicine and companion diagnostics; the company states that the Southeast Asian NGS diagnostics market is projected to grow from roughly KRW 1.5 trillion in 2022 to KRW 3 trillion by 2030, implying an annual growth rate of about 17.6%.
Minimal residual disease (MRD) diagnostics is a particularly fast-growing sub-segment globally, and competition is intensifying domestically as multiple new entrants pursue mass-spectrometry-based protein assays and circulating-tumor-cell analysis among other approaches.
The domestic NGS diagnostics market is structured around large hospitals as the primary supply channel, and NGeneBio has a track record of supplying more than 25 major medical institutions.
In overseas markets, region-specific regulatory hurdles-EU IVDR certification and US CLIA lab compliance-remain a key variable for expansion.
In Southeast Asia, the introduction of national insurance reimbursement schemes is a key driver of demand growth, with Thailand's confirmation of insurance coverage for preemptive breast-cancer screening cited as a notable example.
Overall, the industry is in a growth phase, but competition for market share is intensifying as numerous small and mid-sized precision diagnostics firms enter simultaneously.
The company has stated plans to expand supply of its NGeneAnalySys diagnostic software and to newly build and upgrade its next-generation genomic data management system NGLIS in the second half.
In AI precision medicine, it intends to commercialize its NPAS software to secure new revenue streams through drug-development research collaborations with pharmaceutical firms and integrated AI-NGS companion diagnostics.
Building on EU CE-IVDR certification for its breast and ovarian cancer diagnostic panel, the company expects to accelerate global expansion of its hereditary cancer and solid-tumor panels.
In Southeast Asia, it announced supply to four major Vietnamese hospitals in the second half of this year, and in Thailand, new supply has been confirmed following the reimbursement decision for preemptive breast-cancer screening.
In blood-cancer monitoring, the company registered an AML MRD diagnostic patent jointly with Seoul St. Mary's Hospital and plans to build out an MRD diagnostic portfolio across multiple cancer types using the associated panel.
Financially, the company is attempting to repair its balance sheet through a 3-for-1 capital reduction and a roughly KRW 22.4bn rights offering carried out in the first half of 2026, and whether these proceeds translate into actual debt reduction and improved liquidity remains a key point to watch going forward.
Net losses have continued through the most recent four reported quarters, putting the price-to-earnings ratio in a range that cannot be meaningfully calculated in the conventional way.
The price-to-book ratio sits below 1x, meaning the shares trade at a discount to accounting net asset value, which can be read as reflecting years of accumulated losses and capital erosion. The company pays no dividend, so dividend-yield-based comparisons carry limited relevance.
Looking at annual results alone, both the operating loss and net loss have shown a narrowing trend since bottoming out in 2024, but the alternating pattern of quarterly profit and loss suggests the company has not yet settled into a stable earnings trajectory.
Share dilution from the rights offering and the recalculation effects on per-share metrics from the capital reduction are additional factors to weigh.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The diagnostics segment continues to grow evenly at home and abroad, driven by expanded sales of blood-cancer and solid-tumor precision diagnostic products and rising test demand at major hospitals.
Diagnostics revenue rose 80.7% year-on-year in Q2 2026, with both domestic and overseas sales up by double digits or more. EU CE-IVDR certification and expanded hospital supply in Southeast Asia indicate this growth is broadening geographically.
The company pursued a combination of a 3-for-1 capital reduction and a roughly KRW 22.4bn rights offering in the first half of 2026 to bolster capital.
This represents an attempt to repair a capital structure eroded by accumulated losses, and if completed successfully could help improve the debt ratio and liquidity metrics.
There have also been instances of management signaling participation in prior capital raises, making the completion of fundraising a key variable going forward.
Through its EXAONE Path 2.0 licensing agreement with LG AI Research, the company is pursuing commercialization of its NPAS AI pathology-analysis software, seeking new revenue through drug-development research collaborations with pharmaceutical companies and integrated AI-NGS companion diagnostics.
An AML MRD diagnostic patent jointly registered with Seoul St. Mary's Hospital provides a technical basis for expanding its blood-cancer monitoring portfolio. The company continues to pursue business diversification built on genomic data accumulated through its diagnostics operations.
Operating and net losses persisted every year from 2022 through 2025, and operating cash flow was negative in all four years.
Even in 2025 when revenue expanded significantly, the company posted an operating loss of KRW 8.3bn and a net loss of KRW 6.8bn, showing that top-line growth has not directly translated into improved profitability.
Net losses continued in both Q1 and Q2 2026, suggesting it will take more time to reach a stable earnings trajectory.
The debt ratio jumped from 86.1% in 2024 to 220.2% in 2025, and during this period market commentary flagged a funding structure involving convertible-bond-financed real estate purchases that were then pledged as collateral for the same bonds.
This was followed by a 3-for-1 capital reduction and a large rights offering in succession, repeatedly diluting existing shareholders.
The underwriter of one rights offering reportedly set a forfeiture fee above the market average given the deteriorated financial condition, suggesting funding conditions were not favorable.
NGenePharma, the driver of 2025 revenue growth, was reportedly a low-margin distribution business that was not profitable even at the time of acquisition, raising the risk that low-margin operations could take up a growing share of the revenue mix.
There have also been periods in which the diagnostics segment saw revenue decline due to delayed product launches and weak sales, meaning uncertainty around new-product commercialization timelines could affect results.
The repeated history of mergers, acquisitions and changes in controlling shareholder could raise questions about execution capability in integrating these businesses.
The debt ratio rose to 220.2% at the end of 2025, and cash and cash equivalents are reported to have shrunk significantly. With operating cash flow negative for four consecutive years, reliance on external financing is high, and the possibility of further borrowing or capital raises going forward cannot be ruled out. Deteriorating financing conditions could constrain execution of the company's business plans.
After the controlling shareholder changed from KT to SH Healthcare Investment Fund No.1, a series of large acquisitions, rights offerings and a capital reduction followed in succession.
Any further capital raises could dilute existing shareholders further, and changes in governance could also affect the consistency of management strategy.
The expanding share of low-margin pharmaceutical distribution revenue following the NGenePharma consolidation could steer the business mix in an unintended direction.
Given past instances where delayed launches of new diagnostic products temporarily reduced revenue, any delay in commercializing new platforms such as NPAS and NGLIS could also disrupt plans to secure new revenue streams.
The Q3 quarterly report will show whether the diagnostics revenue growth trend and the narrowing operating loss continue.
It will be worth checking, via the debt ratio in upcoming financial statements, whether proceeds from the first-half rights offering and capital reduction actually translated into debt reduction and improved liquidity.
Progress on commercializing the NPAS AI pathology-analysis software, and whether it generates revenue through drug-development collaborations or companion diagnostics, should be monitored.
Whether new hospital supply contracts in Vietnam, Thailand and other Southeast Asian markets are actually reflected in revenue, and progress on the US CLIA lab business, warrant continued monitoring.
NGeneBio has seen a clear expansion in revenue since 2025, driven by the NGenePharma consolidation and domestic and overseas growth in its NGS diagnostics business, with the operating loss ratio improving from a 2024 trough.
Multiple growth threads are progressing in parallel, including EU CE-IVDR certification, Southeast Asian market expansion, and a new AI precision-medicine business built on collaboration with LG AI Research.
However, financial strain remains unresolved, evidenced by four consecutive years of negative operating cash flow, a debt ratio that climbed to 220.2% in 2025, and successive rounds of capital reduction and rights offerings.
Quarterly results have also yet to show clear stabilization, swinging from a one-off net profit in Q4 2025 back to net losses in both Q1 and Q2 2026.
Key points to watch going forward are whether the rights-offering proceeds translate into genuine balance-sheet improvement, and how quickly revenue generation from diagnostics and the new AI business can accelerate the pace of earnings improvement.
Both the financial risks and the growth narrative warrant balanced consideration before forming an investment judgment.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.